Study to Evaluate the Analgesic Efficacy of 28 Days' Oral Administration of AZD2066 Compared With Placebo in Patients With Painful Diabetic Neuropathy

PHASE2CompletedINTERVENTIONAL
Enrollment

127

Participants

Timeline

Start Date

February 28, 2009

Primary Completion Date

August 31, 2009

Study Completion Date

August 31, 2009

Conditions
PainDiabetic Neuropathy
Interventions
DRUG

AZD2066

Capsule, once daily, 12 mg AZD2066 day 1-4 and 18 mg AZD2066 day 5-28.

DRUG

Placebo

Capsule, once daily

Trial Locations (19)

Unknown

Reserach Site, Bella Vista

Research Site, National City

Research Site, Walnut Creek

Research Site, Clearwater

Research Site, DeLand

Research Site, Lauderdale Lakes

Research Site, Miami

Research Site, Orlando

Research Site, Pembroke Pines

Research Site, Madisonville

Research Site, Owing Mills

Research Site, Bingham Farms

Research Site, Willingboro

Reasearch Site, Albany

Research Site, Winston-Salem

Research Site, Indiana

Research Site, Philadelphia

Research Site, Houston

Research Site, San Antonio

Sponsors

Lead Sponsor

All Listed Sponsors
lead

AstraZeneca

INDUSTRY